HomeBusiness NewsNeurodegenerative Disorder Market Share, Trend, Segmentation and Forecast to 2033

Neurodegenerative Disorder Market Share, Trend, Segmentation and Forecast to 2033

The Neurodegenerative Disorder Market in the United States is expected to experience a robust growth rate, with a projected 6.7% compound annual growth rate (CAGR), reaching a valuation of US$ 1.1 billion by the year 2033. The growing elderly population is expected to contribute to the rising prevalence of neurodegenerative disorders. Increased funding for research initiatives focused on neurodegenerative diseases and the early detection of neurological conditions are anticipated to propel market expansion within the nation.

As per Fact.MR’s analysis, the global neurodegenerative disorder market size is poised to grow, with its estimated worth expected to surge from US$ 3.6 billion in 2023 to reach a substantial US$ 6.8 billion by the year 2033. This growth is anticipated to be underpinned by a steady rise in global revenue derived from neurodegenerative disorder therapies, with a projected compound annual growth rate (CAGR) of 6.7% from 2023 to 2033.

Download a Sample Copy of This Report: 

Neurodegenerative disorders, a class of diseases characterized by the progressive degeneration of the nervous system, have long posed significant challenges to healthcare providers and researchers. Conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) affect millions of individuals worldwide and have been associated with significant human suffering and high healthcare costs. However, recent years have witnessed remarkable breakthroughs in the management of neurodegenerative disorders, offering new hope for patients and their families.

Precision Medicine and Personalized Therapies

One of the most significant advancements in the field of neurodegenerative disorder management is the move towards precision medicine. Researchers are now able to better understand the genetic and molecular underpinnings of these diseases, allowing for more targeted and personalized treatment approaches. This shift from a one-size-fits-all approach to tailored therapies has led to improved outcomes and reduced side effects for patients.

Disease-Modifying Therapies

Traditionally, many treatments for neurodegenerative disorders focused on symptom management rather than addressing the underlying causes of these conditions. However, recent breakthroughs have paved the way for disease-modifying therapies that aim to slow or even halt the progression of these diseases. For instance, drugs targeting beta-amyloid and tau proteins in Alzheimer’s disease are showing promise in clinical trials, potentially altering the course of the disease.

Competitive Landscape

Numerous companies operating within the global neurodegenerative disorders market are channeling substantial investments into research and development endeavors. Key players frequently employ strategies like mergers, acquisitions, and expanding their product portfolios. Market leaders are also embracing innovative approaches, including new advancements and unique marketing strategies, in their pursuit of augmenting their market presence.

In a noteworthy announcement made in September 2022, Amylyx Pharmaceuticals disclosed that the FDA had granted approval for RELYVRIO (comprising sodium phenylbutyrate and taurursodiol) as a medical treatment for adults afflicted by amyotrophic lateral sclerosis (ALS).

Furthermore, in January 2021, Mitsubishi Tanabe Pharma America, a subsidiary of the parent company in the United States, forged a license and supply agreement with Aquestive Therapeutics Inc. to secure the rights for Riluzole oral film in the United States, a therapeutic agent specifically designed for ALS.

Key Segments of Neurodegenerative Disorder Industry Research

  • By Diagnosis & Treatment :
    • Diagnosis
      • Inpatient
      • Outpatient
    • Treatment
      • Drugs
        • Riluzole
        • Edaravone
      • Therapy
        • Breathing & Feeding Care
        • Physical Therapy
        • Occupational Therapy
        • Speech Therapy
      • Assistive Technology Devices
        • Brain-computer Interfaces
        • Human-computer Interfaces
        • Speech Generating Devices
        • Communication Boards and Symbol Devices
        • Other Assistive Devices
  • By Indication :
    • Amyotrophic Lateral Sclerosis (ALS)
    • Locked-in Syndrome (LIS)
  • By Distribution Channel :
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Drug Stores
    • Online Pharmacies
    • e-Commerce
    • Supermarkets
  • By Service Provider :
    • Hospitals
    • Specialty Clinics
    • Rehabilitation Centers
    • Home Care Settings
    • Nursing Care Settings
    • Diagnostic Centers
  • By Region :
    • North America
    • Latin America
    • Europe
    • South Asia
    • East Asia
    • Oceania
    • Middle East and Africa

Get Customization on this Report:

The neurodegenerative disorder market is currently witnessing a transformative phase with breakthroughs in disease management. These developments are offering renewed hope for patients and their families who have long grappled with the devastating effects of these conditions. As researchers continue to unravel the mysteries of these disorders, it is increasingly likely that new and more effective therapies will emerge, ultimately changing the landscape of neurodegenerative disorder management. These innovations represent a beacon of hope in the quest for improved quality of life and a potential cure for those affected by these debilitating diseases.

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com